It's their only option to go knocking on the door of big pharma...

It's their only option to go knocking on the door of big pharma and to give away a much larger chunk or to sell up completely. Hopefully they realise their dire position before it's too late, but I wouldn't bank on it given they failed to deliver on a licensing deal when in a much better position. The ongoing costs are a major concern (8-11 million per Q) with 30 million cash left. If PR doesn't turn things around in the next 6 months then we can say goodbye to trialing iPPS in the US and EU markets, but instead will only be able to focus on the much smaller AU market with max 100 million p.a revenue potential IMO.

You really only get one shot in this business.